Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2/3 1Phase 2 1

Status

Withdrawn 1Terminated 1Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Ovarian Neoplasms 69Fallopian Tube Neoplasms 18Endometrial Neoplasms 8Carcinoma, Ovarian Epithelial 8Breast Neoplasms 7Neoplasms 5Pancreatic Neoplasms 3Cystadenocarcinoma, Serous 3Uterine Neoplasms 2Uterine Cervical Neoplasms 2Urogenital Neoplasms 2Prostatic Neoplasms 2Ovarian Diseases 2Neoplasm Metastasis 2Gonadal Disorders 2Genital Neoplasms, Female 2Genital Diseases, Female 2Endocrine System Diseases 2Endocrine Gland Neoplasms 2Carcinoma 2Adnexal Diseases 2Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocytopenia 1Sarcoma 1Recurrent/ Advanced Stage Endometrial Cancer Patients 1Recurrence 1Prostatic Diseases 1Platinum-resistant Recurrent Clear Cell Ovarian Cancer 1Platinum-resistant Ovarian Cancer 1

Interventions

niraparib 3pembrolizumab 1Specimen Handling 1Paclitaxel 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Diphenhydramine 1Dexamethasone 1Cimetidine 1CTLA-4 Antigen 1Blood Specimen Collection 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Cystadenocarcinoma, Serous × niraparib × Gynecologic × Clear all
NCT04159155 2025-08-12

CAN-STAMP

University Health Network, Toronto

Phase 2/3 Terminated
11 enrolled
Gynecologic

Endometrial Neoplasms, Cystadenocarcinoma, Serous

NCT05289648 2024-12-19

NIREC

Sir Mortimer B. Davis - Jewish General Hospital

Phase EARLY_PHASE1 Withdrawn
Gynecologic

Uterine Neoplasms, Endometrial Neoplasms, Cystadenocarcinoma, Serous

NCT04716686 2024-01-05

Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma

Shandong University

Phase 2 Recruiting
83 enrolled
Gynecologic

Endometrial Neoplasms, Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡